Travoprost Five Day Posology Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Fort Worth, Texas, United States, 76134
- Contact Alcon Call Center for Trial Locations
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- either sex and any race/ethnicity, ≥18 years old
- diagnosed with open-angle glaucoma, and/or ocular hypertension
meets the following IOP entry criteria:
- Mean IOP ≥ 24 millimeters mercury (mmHg) in at least 1 eye, with the same eye qualifying at 8 AM on both the Eligibility Visit (Day 0) and Day 1
- Mean IOP ≤ 36 mmHg in both eyes at 8 AM and 8 PM at the Eligibility Visit (Day 0), and at 8 AM on Day 1
- satisfies all informed consent requirements; able to read, sign and date the informed consent
Exclusion Criteria:
- females of childbearing potential not meeting protocol conditions
- angle grade less than Grade 2 in either eye
- cup to disc ratio greater than 0.8 (horizontal or vertical measurement) in either eye
- severe central visual field loss in either eye
- any abnormality preventing reliable applanation tonometry in either eye
- hypersensitivity to prostaglandin analogues or to any component of the study medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: TRAVATAN
TRAVATAN 0.004% once daily
|
1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
|
|
Placebo Comparator: Travoprost Vehicle
|
1 drop in each eye 8 times daily for 5 days
|
|
Experimental: Travoprost Group A
|
1 drop in each eye 8 times daily for 5 days
|
|
Experimental: Travoprost Group B
|
1 drop in each eye 8 times daily for 5 days
|
|
Experimental: Travoprost Group C
|
1 drop in each eye 8 times daily for 5 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Intraocular Pressure (IOP) Change From Baseline at 8 AM on Day 5
Time Frame: 5 days
|
Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment
|
5 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
IOP Change From Baseline at 8 PM on Day 5
Time Frame: 5 Days
|
Outcome measure shows how each treatment reducted eye pressure at 8 PM on Day 5 compared to the eye pressure at 8 PM before the start of treatment
|
5 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- C-09-075
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.